ADPT icon

Adaptive Biotechnologies

17.27 USD
+0.16
0.94%
At close Updated Oct 16, 4:00 PM EDT
Pre-market
After hours
17.28
+0.01
0.06%
1 day
0.94%
5 days
9.37%
1 month
33.77%
3 months
59.46%
6 months
130.57%
Year to date
179%
1 year
259.79%
5 years
-66.59%
10 years
-57.15%
 

About: Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Employees: 619

0
Funds holding %
of 7,495 funds
0
Analysts bullish %
of 5 analysts
Positive news %
of articles
Price charts implemented using Lightweight Charts™